A research team at UC Davis Health in Sacramento has completed what the institution calls the world’s first treatment combining open fetal surgery with a stem-cell–seeded patch to repair spina bifida before birth. The Phase 1 safety results, now published, found no serious adverse events tied to the stem cells, and none of the treated babies required a shunt for hydrocephalus before hospital discharge. The findings raise a sharp question for fetal medicine: can adding living cells to a surgical patch protect the developing nervous system better than surgery alone, potentially reducing paralysis?
What the CuRe Trial Actually Did
The procedure, known as the CuRe Trial, is described as a first-in-human Phase 1 single-arm study, though its trial registration lists the design as Phase 1/2a. Surgeons opened the uterus at roughly 24 to 25 weeks gestational age and placed an extracellular-matrix scaffold seeded with live placenta-derived mesenchymal stromal cells (often described as mesenchymal stem cells) directly over the exposed spinal cord defect, the hallmark of myelomeningocele, the most severe form of spina bifida. Babies were then delivered preterm, around 34 weeks, in line with timing described in a recent news report that profiled the first families enrolled in the study and outlined the logistics of coordinating maternal–fetal surgery with neonatal intensive care.
The trial, which began in June 2021 according to its clinical registration, has a planned completion around March 2027 and is enrolling up to 35 participants. Its eligibility criteria reference those of the landmark MOMS Trial, the randomized controlled study that first proved prenatal surgery was superior to postnatal repair for myelomeningocele. That earlier work, published in the New England Journal of Medicine and summarized in an open-access follow-up analysis, showed that fetal surgery reduced the need for cerebrospinal fluid shunts, reversed hindbrain herniation, and improved motor outcomes at 30 months. But the MOMS Trial also documented real maternal and fetal risks, including uterine dehiscence and preterm birth, which is why the CuRe Trial’s first job was proving that adding stem cells did not make an already complex surgery more dangerous.
Sheep Studies That Built the Case
The clinical trial did not emerge from theory alone. Years of preclinical work in an ovine fetal repair model showed that placental mesenchymal stromal cells seeded onto clinical-grade extracellular matrix improved ambulation compared with the scaffold material alone. Researchers quantified the difference using the Sheep Locomotor Rating scale and found that treated lambs also had higher large-neuron density in their spinal cords, a sign that the cells were protecting the nervous tissue from the progressive damage that amniotic fluid inflicts on an exposed spinal cord throughout gestation. Histologic analyses suggested that the stem cells might exert both structural and trophic effects, helping preserve gray matter and limiting the secondary injury that typically follows the initial neural tube defect.
A follow-up study tested varying densities of placental mesenchymal stromal cells on the same extracellular matrix scaffold. That work reported SLR motor scores, spinal cord and gray matter cross-sectional areas, and large-neuron density, along with correlation statistics linking neuron density to motor outcomes. Higher cell-seeding densities tracked with better walking ability in the lambs, and the investigators reported a dose–response relationship between the number of cells applied and the preservation of spinal cord architecture. Animal modeling over the course of the research program suggested improved locomotion in this species, according to the University of California, and those data formed part of the scientific backbone that regulators reviewed before authorizing first-in-human testing.
Earlier Precedent for Fetal Stem Cells
The CuRe Trial is not the first time scientists have delivered stem cells to a fetus. In a separate case documented in The Lancet, a patient with severe osteogenesis imperfecta, a genetic condition that causes extremely fragile bones, received fetal mesenchymal stem cells before birth. Researchers confirmed donor-cell engraftment using Y-chromosome fluorescence in situ hybridization assays and tracked the child’s early clinical course, including fracture frequency and growth. The report also detailed immunologic findings and careful surveillance for malignancy; no tumor formation was observed during the period of follow-up. Although this was a single case, it showed that donor cells can integrate into developing fetal tissues and survive long enough to exert clinically relevant effects.
This tolerance is central to the logic behind the CuRe Trial. Because the fetal immune system is still developing, stem cells introduced during pregnancy face a lower barrier to survival and function than they would in an adult recipient. The osteogenesis imperfecta case targeted bone; the spina bifida work targets nerve tissue. Different organs, different diseases, but the same biological window of opportunity when the fetus is primed to accept foreign cells with minimal rejection. The question that remains unanswered, and that no Phase 1 safety trial is designed to address, is whether the cells actually improve long-term neurological function in humans the way they did in sheep. Answering that will require years of follow-up and, ideally, comparative data against standard prenatal repair.
What the Safety Data Does and Does Not Show
The UC Davis Health announcement highlights that none of the treated patients required a shunt for hydrocephalus before hospital discharge. That is a meaningful early signal, since the MOMS Trial established that shunt placement is one of the clearest markers distinguishing prenatal from postnatal repair outcomes. The new report also emphasizes that there were no serious adverse events attributed to the stem cells themselves, no evidence of tumor formation on early imaging, and no unexpected maternal complications beyond what is typically seen with open fetal surgery. These findings suggest that layering a stem-cell–seeded patch onto standard prenatal repair does not introduce obvious short-term harms in this small cohort.
At the same time, Phase 1 studies are built to detect harm, not to prove benefit. The CuRe Trial enrolled a limited number of patients, had no control arm, and was not powered to draw conclusions about whether the stem cells improved motor function, continence, or quality of life. Outcomes such as independent walking, need for assistive devices, and bladder or bowel control will unfold over years, not months. Without randomization or a matched comparison group, any early differences in shunt rates or motor milestones must be interpreted cautiously, especially given the variability inherent in myelomeningocele severity and surgical technique. Long-term surveillance will also be needed to rule out late-emerging complications such as tethered cord or abnormal tissue growth at the repair site.
How This Fits Into the Larger Stem Cell Landscape
The CuRe Trial sits within a broader and often confusing landscape of stem cell interventions, many of which lack rigorous data. Reputable investigators typically ground their work in preclinical models, register studies prospectively, and publish results in peer-reviewed venues indexed in resources like major biomedical databases. By contrast, unregulated clinics sometimes market “stem cell cures” for neurological conditions without animal data, trial registration, or systematic safety monitoring. The careful stepwise progression from sheep experiments to a monitored human Phase 1 study distinguishes the UC Davis effort from such commercial offerings and underscores the importance of regulatory oversight when live cells are introduced into vulnerable patients.
For families facing a prenatal diagnosis of spina bifida, the emergence of a combined surgical and cellular therapy is both hopeful and fraught. On one hand, the possibility of reducing paralysis or improving bladder function is profoundly compelling, and the absence of early stem-cell–related complications is reassuring. On the other hand, participation in a first-in-human trial entails additional uncertainty on top of the known risks of open fetal surgery, including preterm birth and maternal uterine scarring that can affect future pregnancies. As the CuRe Trial moves into later phases and accumulates longer-term data, clinicians will need to balance enthusiasm with transparency, clearly explaining that the current evidence supports safety in the short term but has not yet demonstrated superior functional outcomes compared with established prenatal repair alone.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
